Gadopentetate Intravenous and High Blood Pressure (Hypertension)

Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes). Always estimate the glomerular filtration rate (GFR) through laboratory testing.

Gadolinium- based contrast agents (GBCAs) such as gadopentetate dimeglumine, gadoteridol and gadodiamide are contraindicated in patients with chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min), or acute kidney injury. GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Their use should be avoided in these patients unless the diagnostic information is essential and not available with non- contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. Caution is advised in patients at risk for chronically reduced renal function (age >60 years, hypertension or diabetes). Always estimate the glomerular filtration rate (GFR) through laboratory testing.